Skip to main content

MoonLake Immunotherapeutics

MLTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001821586

In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding MoonLake Immunotherapeutics changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of MLTX: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders125114−11
Shares59.3M59.5M+192.3K (+0.3%)
Value$3.53B$2.99B−$539.2M (−15.3%)

New holders (22)

Institutions that held MoonLake Immunotherapeutics at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to MLTX in Q1 2024
InstitutionSharesValue% of portfolio
Marshall Wace, LLP510,946$25.7M0.04%
Decheng Capital LLC166,600$8.37M1.12%
Walleye Capital LLC136,429$6.85M0.07%
Monashee Investment Management LLC115,000$5.78M0.68%
Duquesne Family Office LLCSuperinvestorDuquesne Family Office87,500$4.39M0.12%
Clearbridge Investments, LLC28,551$1.43M0.00%
Resolute Capital Asset Partners LLC24,541$1.23M0.64%
J. Goldman & Co LP17,107$859.3K0.04%
Erste Asset Management GmbH15,000$753.1K0.01%
SG Americas Securities, LLC14,458$726.0K0.00%
Group One Trading, L.P.13,520$679.1K0.02%
Trexquant Investment LP9,697$487.1K0.01%
Harbor Capital Advisors, Inc.8,208$412.0K0.05%
Danske Bank A/S7,780$390.8K0.00%
Diametric Capital, LP7,696$386.6K0.21%
DnB Asset Management AS5,678$285.2K0.00%
Catalyst Funds Management Pty Ltd4,800$241.1K0.07%
Bellevue Group AG4,400$221.0K0.00%
Cinctive Capital Management LP4,213$211.6K0.01%
ADAR1 Capital Management, LLC3,000$150.7K0.04%
Belvedere Trading LLC2,201$110.6K0.01%
KBC Group NV565$28.0K0.00%

Sold out (33)

Institutions that held MoonLake Immunotherapeutics at the end of Q4 2023 and filed for Q1 2024 without it.